Last reviewed · How we verify
ATG Fresenius
ATG Fresenius is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity.
ATG Fresenius is a polyclonal antithymocyte globulin that depletes T lymphocytes by binding to T-cell antigens and triggering complement-mediated and antibody-dependent cellular cytotoxicity. Used for Prevention of acute organ rejection in allogeneic transplantation, Treatment of aplastic anemia, Treatment of acute graft-versus-host disease.
At a glance
| Generic name | ATG Fresenius |
|---|---|
| Also known as | Simulect IV 40 mg/day D0 and D4, and oral use Tacrolimus 0.1 mg/ kg/ day +, Myfortic 720 to 1440mg +, Corticosteroids 5mg |
| Sponsor | University Hospital, Basel, Switzerland |
| Drug class | Polyclonal antithymocyte globulin (ATG) |
| Target | T-cell surface antigens (CD2, CD3, CD4, CD8, CD25, HLA-DR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
ATG Fresenius is derived from rabbit serum immunized against human thymocytes. It contains polyclonal antibodies that recognize multiple epitopes on T cells, leading to T-cell depletion through complement activation and opsonization. This immunosuppressive effect is used to prevent graft rejection and treat aplastic anemia by reducing the T-cell mediated immune response.
Approved indications
- Prevention of acute rejection in renal transplantation
- Treatment of aplastic anemia
- Prevention of graft-versus-host disease in hematopoietic stem cell transplantation
Common side effects
- Fever
- Chills
- Leukopenia
- Thrombocytopenia
- Serum sickness
- Infection
Key clinical trials
- Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
- Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
- Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation (PHASE2)
- Multicenter Study of Peritransplantation Immunosuppression for Mismatched Hematopoietic Cell Transplantation After Reduced Intensity Conditioning (PHASE2)
- Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies (PHASE2)
- Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment (PHASE4)
- Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT (PHASE1)
- ATG-F VS ATG for the Prevention of GVHD (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ATG Fresenius CI brief — competitive landscape report
- ATG Fresenius updates RSS · CI watch RSS
- University Hospital, Basel, Switzerland portfolio CI